- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03085186
Treatment With Crizotinib Single Patient Expanded Access IND 134375
Two year old male with a new diagnosis of Inflammatory Myofibroblastic Tumour. The patient presented with 2 months of intermittent fever and 1-2 weeks of abdominal distention and constipation. An abdominal mass was palpable on exam and US concerning was for neoplasm of abdomen.
Treatment with Crizotinib will be utilized to reduce the size of the lesion and create more optimal tissue plains between vital structures prior to attempted surgical resection would greatly reduce potential morbidity for this patient.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Expanded Access Type
- Individual Patients
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- This treatment plan is intended for the use of Crizotinib in the treatment of a single patient with Inflammatory Myofibroblastic Tumour
Exclusion Criteria:
- Not applicable as Expanded Access only includes one patient
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO17030033
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Myofibroblastic Tumour
-
Sun Yat-sen UniversityUnknownInflammatory Myofibroblatic TumorChina
-
Federal Research Institute of Pediatric Hematology...UnknownInflammatory Myofibroblastic TumorRussian Federation
-
TakedaWithdrawnSolid Tumors | Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumors
-
Second Affiliated Hospital, School of Medicine,...Active, not recruiting
-
University of LeicesterUniversity of Nottingham; Nottingham University Hospitals NHS TrustCompleted
-
Cairo UniversityCompleted
-
Zhejiang Provincial People's HospitalRecruiting
-
AstraZenecaParexelCompleted
-
CrystalGenomics, Inc.UnknownSolid TumourKorea, Republic of
-
AstraZenecaCompletedSolid TumourUnited States
Clinical Trials on Crizotinib
-
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...Not yet recruitingNon-Small Cell Lung CancerUnited States
-
PfizerWithdrawnCarcinoma, Renal Cell | Glioblastoma | Carcinoma, Hepatocellular
-
Samsung Medical CenterCompletedc-MET Positive Gastric CancerKorea, Republic of
-
PfizerCompletedRenal ImpairmentUnited States
-
PfizerCompleted
-
European Organisation for Research and Treatment...PfizerCompletedLocally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma | Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor | Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1 | Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma | Locally Advanced... and other conditionsFrance, Belgium, Netherlands, Germany, United Kingdom, Italy, Norway, Poland, Slovakia, Slovenia
-
PfizerCompleted
-
PfizerCompletedHealthy VolunteerUnited States